Neuromodulators, dermal fillers, biostimulators, and the longevity question. Label-first, comparison-shaped.
A regulatory and clinical profile analyzing Prollenium's Revanesse filler line, its single FDA PMA P160042 architecture, Thixofix cross-linking, and MAUDE safety data.
A regulatory and clinical profile analyzing Teoxane's RHA Collection, its single FDA PMA P170002 architecture, Preserved Network Technology, and post-market safety data.
An evidence-based guide to hyperdiluted Radiesse (calcium hydroxylapatite) for skin tightening and body biostimulation, detailing dilution protocols, FDA PMA status, and…
A clinical comparison of Type A (Botox) and Type B (Myobloc) neuromodulators, detailing their distinct molecular targets, duration, pH levels, and FAERS safety data.
A review of the newest FDA dermal filler approvals (Evolysse, saypha MagIQ, Belotero Volume) under product code LMH. Compares chemistry, cross-linking technology, PMA…
A clinical, evidence-first comparison of the only two FDA-approved dermal fillers for hand rejuvenation, reviewing chemical mechanisms, pivotal trials, and safety…
A head-to-head clinical comparison of Xeomin and Jeuveau, analyzing BLA approval histories, purification chemistry, unit conversion ratios, and post-market safety data.
A comprehensive regulatory dossier analyzing AbbVie/Allergan Aesthetics' approvals, BIOCELL textured breast implant recalls, and CoolSculpting and Juvéderm adverse…
An evidence-based pre-treatment guide on blood thinners and supplements for Botox and fillers, analyzing bruising mechanisms, prescription protocols, and technique…
A comprehensive regulatory dossier analyzing Merz Aesthetics' portfolio, Xeomin's BLA registration, Radiesse's and Belotero's PMA history, and Ultherapy PRIME's FDA…